References
- Guidance for industry. Patient-reported outcome measures: use in medical product development and labeling claims. FDA/Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research/Center for Devices and Radiological Health, 2006. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071975.pdf. [last accessed 14 September 2009]
- Marra G, DIAB. & TE.S Study Group. The DIAB. & TE.S Project: how patients perceive diabetes and diabetes therapy. Acta Biomed 2004;75:164-70
- Charpentier G, Fleury F, Dubroca I, et al. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diab Metab 2005;31:189-95
- Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In Handbook of Psychology and Diabetes: a Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers, 1994:111-32
- Peyrot M, Rubin RR. Assessing health-related quality of life and treatment preferences: the Insulin Delivery System Rating Questionnaire (IDSRQ). Diabetes Care 2005;28:53-8
- Rubin RR, Peyrot M. Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. The Diabetes Educator 2009;35:136-46
- Ware JH, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36). I: Conceptual framework and item selection. Med Care 1992;30:473-83
- Boyer JG, Earp JL. The development of an instrument for assessing the quality of life of people with diabetes. Med Care 1997;35:440-53
- Polonsky WH, Fisher L, Earles J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care 2005;28:626-31
- Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2:113-27
- Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189-95
- Hollander PA, Levy P, Fineman MS, et al. Pramlintide therapy as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2003;26:784-90
- SYMLIN [package insert]. San Diego, CA, Amylin Pharmaceuticals, 2005
- Whitehouse F, Kruger DF, Fineman MS, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724-30
- Ratner RE, Dickey R, Fineman MS, et al. Amylin replacement with pramlintide as adjunct to insulin therapy improves long-term glycemic and weight control in type 1 diabetes mellitus: a one-year randomized controlled trial. Diabet Med 2004;21:1204-12
- Marrero DG, Crean J, Zhang B, et al. Effect of pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 2007;30:210-16
- Rubin RR, Peyrot M. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. Curr Med Res Opin 2007;23:1919-29
- Peyrot M, Rubin RR. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. Diabetes Technol Ther 2008;10:461-6
- Riddle M, Pencek R, Charenkavanich S, et al. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009;32:1577-82
- Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
- Snoek FJ, Pouwer F, Welch GW, et al. Diabetes-related emotional distress in Dutch and U.S. diabetic patients: cross-cultural validity of the Problem Areas in Diabetes scale. Diabetes Care 2000;23:1305-9
- Glasgow RE, Fisher L, Skaff M, et al. Problem solving and diabetes self-management: investigation in a large, multiracial sample. Diabetes Care 2007;30:33-7
- Trento M, Broglio F, Riganti F, et al. Sleep abnormalities in type 2 diabetes may be associated with glycemic control. Acta Diabetol 2008;45:225-9
- Peyrot M, Rubin RR. How does treatment satisfaction work?: modeling determinants of treatment satisfaction and preference. Diabetes Care 2009;32:1411-17
- Peyrot M, Rubin RR, Polonsky WH, et al. Clinical and patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin. Meeting abstract. Diabetes 2009;58(Suppl 1):A474